Premium
Prognostic value of the TCGA molecular classification in uterine carcinosarcoma
Author(s) -
Travaglino Antonio,
Raffone Antonio,
Raimondo Diego,
Arciuolo Damiano,
Angelico Giuseppe,
Valente Michele,
Scaglione Giulia,
D’alessandris Nicoletta,
Casadio Paolo,
Inzani Frediano,
Mollo Antonio,
Santoro Angela,
Seracchioli Renato,
Franco Zani Gian
Publication year - 2022
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.13937
Subject(s) - medicine , serous fluid , carcinosarcoma , oncology , serous carcinoma , carcinoma , endometrial cancer , microsatellite instability , cohort , progression free survival , overall survival , cancer , gene , biology , ovarian cancer , microsatellite , allele , biochemistry
Background The TCGA molecular groups of endometrial carcinoma are “POLE‐mutated” (POLEmut), “microsatellite‐instable/mismatch repair‐deficient” (MSI/MMRd), “TP53‐mutated/p53‐abnormal” (TP53mut/p53abn), and “no specific molecular profile” (NSMP). Objective Prognostic assessment of the TCGA groups in uterine carcinosarcoma (UCS). Search strategy Systematic review from January 2000 to January 2021. Selection criteria Studies assessing the TCGA groups in UCS. Data collection and analysis Progression‐free survival (PFS) and overall survival (OS) were assessed by Kaplan–Meier and Cox analyses (reference: TP53mut/p53abn group) and compared with endometrioid and serous carcinomas (original TCGA cohort), with a significant P < 0.050. Main results Five studies with 263 UCS were included. Compared with TP53mut/p53abn UCS, MSI/MMRd UCS showed significantly better PFS ( P < 0.001) but similar OS ( P = 0.788), whereas NSMP UCS showed similar PFS ( P = 0.936) and OS ( P = 0.240). Compared with their endometrioid/serous counterparts, NSMP and TP53mut/p53abn UCS showed significantly worse PFS ( P < 0.001 and P = 0.004) and OS ( P < 0.001 and P < 0.001), while MSI/MMRd UCS showed similar PFS ( P = 0.595) but significantly worse OS ( P < 0.001). The POLEmut group showed neither recurrences nor deaths in both the UCS and the endometrioid/serous carcinoma cohorts. Conclusion POLEmut UCS show excellent prognosis, whereas TP53mut/p53abn and NSMP UCS show a prognosis even worse than that of TP53mut/p53abn endometrioid/serous carcinomas. The prognosis of MSI/MMRd UCS remains to be defined.